New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
J Neuroimmunol
; 362: 577785, 2022 01 15.
Article
in English
| MEDLINE | ID: covidwho-1559420
ABSTRACT
BACKGROUND:
Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case.CONCLUSION:
Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
BNT162 Vaccine
/
2019-nCoV Vaccine mRNA-1273
/
Multiple Sclerosis
Type of study:
Case report
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Neuroimmunol
Year:
2022
Document Type:
Article
Affiliation country:
J.jneuroim.2021.577785
Similar
MEDLINE
...
LILACS
LIS